A Phase 1 interventional study of HF1K16 /Arm 45 mg/m² and HF1K16 /Arm 90 mg/m² in Solid Tumor, Adult, sponsored by HighField Biopharmaceuticals Corporation. Recruiting at 7 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-16.
Sponsored by HighField Biopharmaceuticals Corporation · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
HF1K16 is an investigational pegylated liposome formulation of All-Trans Retinoic Acid (ATRA) for the induction of remission in patients with acute promyelocytic leukemia (APL) and for the treatment of solid tumors through targeting myeloid derived suppressor cells (MDSCs).
Myeloid Derived Suppressor Cells (MDSCs) play important roles in constituting the immune suppressive environment promoting cancer development and progression. While previous studies had shown that all-trans retinoic acid (ATRA) could induce MDSC differentiation and maturation, the very poor solubility and fast metabolism of the drug limited its applications as an immune-modulator for cancer immunotherapy
HF1K16 is an investigational pegylated liposome formulation with great ATRA dose loading capacity and sustained drug release property. In preclinical studies, HF1K16 was shown to be able to remodel the host systemic immune homeostasis as well as modify tumor microenvironment (TME). It promotes MDSCs maturation into DCs and facilitates immune responses against cancer cells.
HighField Biopharmaceuticals Corporation is the lead sponsor of 6 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The subjects had to be diagnosed by histology and/or cytology with locally advanced or solid tumor. There is no effective standard of care or the patient is intolerant to the standard therapy.
Cohort 5: The subjects must be diagnosed with glioma by histology, and the disease has or progressed after previous treatment, and there is no effective standard treatment or the subject is intolerant to standard treatment.
According to the definition of 1.1, participants must have at least one .
Cohort 5: at least one lesion that can be measured in two dimensions is required ( RANO criteria).
Exclusion Criteria:
Patients have symptomatic central nervous system (CNS) , meningeal metastases, or a primary CNS tumor that is associated with progressive neurological symptoms. Except that the are shown to be stable judged by imaging examination within 4 weeks.
Cohort 5: The above criteria do not apply to the fifth cohort. The fifth cohort allowed inhaled or topical , or hormone therapy at physiological replacement doses due to adrenal insufficiency; short-term (≤7 days) corticosteroids were allowed for prophylaxis (eg, contrast media allergy) or treatment of non- conditions ( For example, delayed-type reactions caused by exposure to allergens); systemic corticosteroids (≥10 mg/day prednisone, or other equivalent corticosteroids) for 7 consecutive days within 14 days of the first dose are not allowed or therapy.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The first dosing group (45 mg/m²) will include a sentinel subject receiving one dose followed by a 7-day safety evaluation interval. Three or more subjects will receive 7 doses of HF1K16 QOD at 45 mg/m2 per cycle of 21 days.
Drug: HF1K16 /Arm 45 mg/m²
The second dosing group will receive oral ATRA at 45mg/m², and three days later HF1K16 QOD at 90 mg/m2 for 7 times per cycle of 21 days.
Drug: HF1K16 /Arm 90 mg/m²
The cohort 3 will receive 7 doses of HF1K16 QOD at 120 mg/m² per cycle of 21 days.
Drug: HF1K16 /Arm 120 mg/m²
The cohort 4 will receive 7 doses of HF1K16 QOD at 160 mg/m² per cycle of 21 days.
Drug: HF1K16 /Arm 160 mg/m²
The cohort 5 will receive 7 doses of HF1K16 QOD at 120 mg or 180mg per cycle of 21 days.
Drug: HF1K16 /Arm 120 mg or 180 mg
HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Incidence of Adverse Events
Defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE V5.0)
Time frame: 30 days after administration
Incidence of dose-limiting toxicities(DLT)
Observe the dose limiting toxicity, and Incidence of dose-limiting toxicities(DLT) will be assessed
Time frame: 21 days after administration
Respiration rate of Vital Signs by stethoscope
Changes from baseline for respiration rate in breaths per minute of Vital Signs
Time frame: 30 days after administration
Red blood cell count in whole blood sample
Changes from baseline for Red blood cell count in whole blood in10\^9 /L
Time frame: 30 days after administration
Ventricular rate of ECG
Changes from baseline for ventricular rate in beats per minute
Time frame: 30 days after administration
Respiration rate in mg μl/h·g of ECG
Changes from baseline for respiration rate in mg μl/h·g
Time frame: 30 days after administration
Heart rate in beats per minute in beats per minute of ECG
Changes from baseline for heart rate in beats per minute
Time frame: 30 days after administration
Blood pressure by sphygmomanometer
Changes from baseline for blood pressure in mmHg, both systolic and diastolic pressures will be assessed.
Time frame: 30 days after administration
Body temperature by thermometer
Changes from baseline for body temperature in Celsius degree
Time frame: 30 days after administration
White blood cell count in whole blood sample
Changes from baseline for white blood cell count in whole blood in 10\^9 /L
Time frame: 30 days after administration
Neutrophil count in whole blood sample
Changes from baseline for neutrophil count in whole blood in 10\^9 /L
Time frame: 30 days after administration
Hemoglobin concentration in g/dL in whole blood sample
Changes from baseline for hemoglobin concentration in g/dL in whole blood
Time frame: 30 days after administration
Prothrombin time in whole blood sample
Changes from baseline for Prothrombin time in s
Time frame: 30 days after administration
International standardized ratio in whole blood sample
Changes from baseline for international standardized ratio
Time frame: 30 days after administration
International sensitivity index in whole blood sample
Changes from baseline for international sensitivity index
Time frame: 30 days after administration
Activated partial thromboplastin time in whole blood sample
Changes from baseline for activated partial thromboplastin time in s
Time frame: 30 days after administration
Total bilirubin concentration in whole blood sample
Changes from baseline for total bilirubin concentration in μmol/L
Time frame: 30 days after administration
ALT concentration in whole blood sample
Changes from baseline for alanine aminotransferase(ALT) concentration in U/L
Time frame: 30 days after administration
AST concentration in whole blood sample
Changes from baseline for aspartate aminotransferase(AST) concentration in U/L
Time frame: 30 days after administration
Total protein concentration in whole blood sample
Changes from baseline for total protein concentration in g/L
Time frame: 30 days after administration
Urea concentration in whole blood sample
Changes from baseline for urea concentration in mmol/L
Time frame: 30 days after administration
Creatinine concentration in whole blood sample
Changes from baseline for creatinine concentration in μmol/L
Time frame: 30 days after administration
Total cholesterol concentration in whole blood sample
Changes from baseline for total cholesterol concentration in mmol/L
Time frame: 30 days after administration
Triglycerides concentration in whole blood sample
Changes from baseline for triglycerides concentration in mmol/L
Time frame: 30 days after administration
HDL-C in whole blood sample
Changes from baseline for high density lipoprotein cholesterol (HDL-C) in mmol/L
Time frame: 30 days after administration
LDL-C in whole blood sample
Changes from baseline for low density lipoprotein cholesterol (LDL-C) in mmol/L
Time frame: 30 days after administration
PR interval by ECG
Changes from baseline for PR interval in ms of ECG
Time frame: 30 days after administration
QRS by ECG
Changes from baseline for QRS in ms of ECG
Time frame: 30 days after administration
QT by ECG
Changes from baseline for QT in ms of ECG
Time frame: 30 days after administration
QTc by ECG
Changes from baseline for QTc in ms of ECG
Time frame: 30 days after administration
Cohort 5: Determination of overall response rate (ORR) according to RANO criteria
ORR is defined as the proportion of participants with complete response or partial response (CR+PR)
Time frame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 weeks
Cohort 5: Duration of response (DOR)
DOR, defined as the time between the start of the subject's first assessment of CR or PR and the first assessment of PD or death from any cause, according to RANO criteria by the investigator
Time frame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 weeks
Cohort 5: disease control rate (DCR)
DCR , defined as the proportion of subjects with a best overall response of CR, PR, or SD in the study as assessed by the investigator according to RANO criteria
Time frame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 weeks
Cohort 5: progression-free survival (PFS).
PFS, defined as the time between the subject's first dose and the onset of (any aspect of) tumor progression or death from any cause
Time frame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 weeks
HF1K16 pharmacokinetic parameters with Cmax
Maximum plasma concentration (Cmax) after administration of HF1K16
Time frame: Up to 48 hours postdose
the overall response rate(ORR) of HF1K16
ORR is defined as the proportion of participants with complete response or partial response (CR+PR)
Time frame: Once every six weeks in the first year, then once every 12 weeks afterwards through study completion, an average of 1 year
Peripheral blood mononuclear cells by whole blood sample
Assessing peripheral blood mononuclear cells after dose in cells/mL
Time frame: Before injection on Day1,7,13, 21 in each cycle(each cycle is 21 days)
AUC48h by plasma concentration of whole blood sample
Area under plasma concentration -time curve from 0 time ot 48 h(AUC0-48) after dose
Time frame: Up to 48 hours postdose
Tmax by plasma concentration of whole blood sample
Peak time (Tmax) after dose
Time frame: Up to 48hours postdose
T1/2 by plasma concentration of whole blood sample
Elimination half-life (T1/2) after dose
Time frame: Up to 48hours postdose
CL by plasma concentration of whole blood sample
Clearance (CL) after dose
Time frame: Up to 48 hours postdose
Vd by plasma concentration of whole blood sample
Volume of distribution(Vd) after dose
Time frame: Up to 48 hours postdose
AUClast by plasma concentration of whole blood sample
Ratios of geometric means of AUClast (Area under the plasma concentration-time curve from zero to time of last quantifiable concentration) after dose
Time frame: Up to 48 hours postdose
Cohort 5: To assess the changes in MDSC after HF1K16 treatment, including changes in MDSC number
Assessing peripheral blood mononuclear cells after dose in cells/mL
Time frame: Before injection on Day1 in each cycle(each cycle is 21 days)
Cohort 5: Incidence of Adverse Events
Defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE V5.0)
Time frame: after administration
Cohort 5: To assess the changes in MDSC after HF1K16 treatment, including changes in MDSC phenotype
Assessment of MDSC phenotype in peripheral blood after drug administration
Time frame: Before injection on Day1 in each cycle(each cycle is 21 days)
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2022 (actual). Primary completion is estimated for Apr 2025, 38 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
HighField Biopharmaceuticals Corporation